Collaboration to Simplify Analysis of Complex Therapeutic Proteins
Symphogen, a clinical-stage antibody oncology-focused company, pioneering the application of complex mAb mixtures for cancer therapy, based near Copenhagen, Denmark. In 2018 a collaboration between Symphogen and Thermo Fisher Scientific was established to:
- Accelerate innovations in biopharmaceutical characterization
- Develop validated, platform workflows for simplified characterization and quality monitoring of complex therapeutic proteins
- Translate biopharmaceutical characterization methods into transferable, routine, compliant solutions
- Gain insights, understanding and alignment with the analytical and regulatory requirements for complex monoclonal antibody mixtures.
Webinars and articles
Biopharmaceutical UHPLC Method Transfer Success
Transferring bio/pharmaceutical ultra-high performance liquid chromatography (UHPLC) methods between UHPLC systems in the same lab, between labs or to an external partner lab can be challenging.
Dr. Kristensen, principal scientist for Symphogen shares his experience with the Vanquish UHPLC platform and experiences of performing complex biopharmaceutical separations between UHPLC systems within one site and in the laboratory of an external partner.
Characterization of Quality Attributes During Pharmaceutical Development of mAb Mixtures
To address product complexity, and meet regulatory demands, Symphogen is looking increasingly to mass spectrometry for qualitative and quantitative control of critical quality attributes (CQAs).
Case studies employing LC MS (Multiple-Attribute Method, MAM) and native mass spectrometry for characterization and control of CQAs during biopharmaceutical development are presented.
Hear Dan Bach Kristensen, Principal Scientist from Symphogen discussing native LC-MS-based lead selection studies and how Chromeleon CDS helps them to acquire, process and evaluate data with a seamless software platform.